Advertisement

The AAPS Journal

, Volume 15, Issue 1, pp 159–171 | Cite as

A Pharmacokinetic Simulation Tool for Inhaled Corticosteroids

  • Benjamin Weber
  • Guenther HochhausEmail author
Research Article

Abstract

The pharmacokinetic (PK) behavior of inhaled drugs is more complicated than that of other forms of administration. In particular, the effects of certain physiological (mucociliary clearance and differences in membrane properties in central and peripheral (C/P) areas of the lung), formulation (as it relates to drug deposition and particle dissolution rate), and patient-related factors (lung function; effects on C/P deposition ratio) affect the systemic PKs of inhaled drugs. The objectives of this project were (1) to describe a compartmental model that adequately describes the fate of inhaled corticosteroids (ICS) after administration while incorporating variability between and within subjects and (2) based upon the model, to provide a freely available tool for simulation of PK trials after ICS administration. This compartment model allows for mucociliary removal of undissolved particles from the lung, distinguishes between central and peripheral regions of the lung, and models drug entering the systemic circulation via the lung and the gastrointestinal tract. The PK simulation tool is provided as an extension package to the statistical software R (‘ICSpkTS’). It allows simulation of PK trials for hypothetical ICS and of four commercially available ICS (budesonide, flunisolide, fluticasone propionate, and triamcinolone acetonide) in a parallel study design. Simulated PK data and parameters agreed well with literature data for all four ICS. The ICSpkTS package is especially suitable to explore the effect of changes in model parameters on PK behavior and can be easily adjusted for other inhaled drugs.

KEY WORDS

compartment model inhaled corticosteroids pharmacokinetics trial simulation 

Notes

ACKNOWLEDGMENTS

We would like to thank Saskia Fuhrmann, Uta Schilling, and especially Bhargava Kandala, for all their assistance with this project.

REFERENCES

  1. 1.
    Global Initiative for Asthma. Global strategy for asthma management and prevention. http://www.ginasthma.org/uploads/users/files/GINA_Report_2011.pdf. Accessed 12 June 2012.
  2. 2.
    Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. http://www.goldcopd.org/uploads/users/files/GOLD_Report_2011_Jan21.pdf. Accessed 12 June 2012.
  3. 3.
    Hochhaus G, Mollmann H, Derendorf H, Gonzalez-Rothi RJ. Pharmacokinetic/pharmacodynamic aspects of aerosol therapy using glucocorticoids as a model. J Clin Pharmacol. 1997;37:881–92.PubMedGoogle Scholar
  4. 4.
    Hochhaus G. New developments in corticosteroids. Proc Am Thorac Soc. 2004;1:269–74.PubMedCrossRefGoogle Scholar
  5. 5.
    Brutsche MH, Brutsche IC, Munawar M, Langley SJ, Masterson CM, Daley-Yates PT, et al. Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: a randomised crossover study. Lancet. 2000;356:556–61.PubMedCrossRefGoogle Scholar
  6. 6.
    Singh SD, Whale C, Houghton N, Daley-Yates P, Kirby SM, Woodcock AA. Pharmacokinetics and systemic effects of inhaled fluticasone propionate in chronic obstructive pulmonary disease. Br J Clin Pharmacol. 2003;55:375–81.PubMedCrossRefGoogle Scholar
  7. 7.
    Harrison LI, Novak CC, Needham MJ, Ratner P. Comparative pulmonary function and pharmacokinetics of fluticasone propionate and salmeterol xinafoate delivered by two dry powder inhalers to patients with asthma. J Aerosol Med Pulm Drug Deliv. 2011;24:245–52.PubMedCrossRefGoogle Scholar
  8. 8.
    Holford NH, Kimko HC, Monteleone JP, Peck CC. Simulation of clinical trials. Annu Rev Pharmacol Toxicol. 2000;40:209–34.PubMedCrossRefGoogle Scholar
  9. 9.
    Brown Jr RA, Schanker LS. Absorption of aerosolized drugs from the rat lung. Drug Metab Dispos. 1983;11:355–60.PubMedGoogle Scholar
  10. 10.
    Schanker LS, Mitchell EW, Brown Jr RA. Species comparison of drug absorption from the lung after aerosol inhalation or intratracheal injection. Drug Metab Dispos. 1986;14:79–88.PubMedGoogle Scholar
  11. 11.
    Edsbacker S, Wollmer P, Selroos O, Borgstrom L, Olsson B, Ingelf J. Do airway clearance mechanisms influence the local and systemic effects of inhaled corticosteroids? Pulm Pharmacol Ther. 2008;21:247–58.PubMedCrossRefGoogle Scholar
  12. 12.
    R Development Core Team. R: A language and environment for statistical computing. http://www.r-project.org/. Accessed 12 June 2012.
  13. 13.
    Wu K, Blomgren AL, Ekholm K, Weber B, Edsbaecker S, Hochhaus G. Budesonide and ciclesonide: effect of tissue binding on pulmonary receptor binding. Drug Metab Dispos. 2009;37:1421–6.PubMedCrossRefGoogle Scholar
  14. 14.
    Byron PR. Prediction of drug residence times in regions of the human respiratory tract following aerosol inhalation. J Pharm Sci. 1986;75:433–8.PubMedCrossRefGoogle Scholar
  15. 15.
    Lee SL, Adams WP, Li BV, Conner DP, Chowdhury BA, Yu LX. In vitro considerations to support bioequivalence of locally acting drugs in dry powder inhalers for lung diseases. AAPS J. 2009;11:414–23.PubMedCrossRefGoogle Scholar
  16. 16.
    O’Riordan TG, Zwang J, Smaldone GC. Mucociliary clearance in adult asthma. Am Rev Respir Dis. 1992;146:598–603.PubMedGoogle Scholar
  17. 17.
    Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Informa Healthcare; 1982. p. 419–24.Google Scholar
  18. 18.
    Krishnaswami S, Hochhaus G, Derendorf H. An interactive algorithm for the assessment of cumulative cortisol suppression during inhaled corticosteroid therapy. AAPS PharmSci. 2000;2:28–37.CrossRefGoogle Scholar
  19. 19.
    Clark AR. Understanding penetration index measurements and regional lung targeting. J Aerosol Med Pulm Drug Deliv. 2012;25:179–87.PubMedCrossRefGoogle Scholar
  20. 20.
    Moellmann HW, Hochhaus G, Tromm A, Froehlich P, Moellmann AC, Krieg M, et al. Pharmcokinetics and pharmacodynamics of budesonide pH-modified release capsules. In: Moellmann HW, May B, editors. Glucocortocoid therapy in chronic inflammatory bowel disease. Norwell: Kluwer; 1996. p. 107–20.Google Scholar
  21. 21.
    Derendorf H, Hochhaus G, Rohatagi S, Mollmann H, Barth J, Sourgens H, et al. Pharmacokinetics of triamcinolone acetonide after intravenous, oral, and inhaled administration. J Clin Pharmacol. 1995;35:302–5.PubMedGoogle Scholar
  22. 22.
    Rohatagi S, Hochhaus G, Mollmann H, Barth J, Galia E, Erdmann M, et al. Pharmacokinetic and pharmacodynamic evaluation of triamcinolone acetonide after intravenous, oral, and inhaled administration. J Clin Pharmacol. 1995;35:1187–93.PubMedGoogle Scholar
  23. 23.
    Borgstrom L. Deposition patterns with Turbuhaler. J Aerosol Med. 1994;7:S49–53.PubMedCrossRefGoogle Scholar
  24. 24.
    Borgstrom L, Bondesson E, Moren F, Trofast E, Newman SP. Lung deposition of budesonide inhaled via Turbuhaler: a comparison with terbutaline sulphate in normal subjects. Eur Respir J. 1994;7:69–73.PubMedCrossRefGoogle Scholar
  25. 25.
    Pitcairn G, Reader S, Pavia D, Newman S. Deposition of corticosteroid aerosol in the human lung by Respimat Soft Mist inhaler compared to deposition by metered dose inhaler or by Turbuhaler dry powder inhaler. J Aerosol Med. 2005;18:264–72.PubMedCrossRefGoogle Scholar
  26. 26.
    Wildhaber JH, Devadason SG, Wilson JM, Roller C, Lagana T, Borgstrom L, et al. Lung deposition of budesonide from turbuhaler in asthmatic children. Eur J Pediatr. 1998;157:1017–22.PubMedCrossRefGoogle Scholar
  27. 27.
    Ryrfeldt A, Andersson P, Edsbäcker S, Tönnesson M, Davies D, Pauwels R. Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. Eur J Respir Dis Suppl. 1982;122:86–95.PubMedGoogle Scholar
  28. 28.
    Thorsson L, Edsbacker S, Conradson TB. Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler P-MDI. Eur Respir J. 1994;7:1839–44.PubMedCrossRefGoogle Scholar
  29. 29.
    Kallen A, Thorsson L. Drug disposition analysis: a comparison between budesonide and fluticasone. J Pharmacokinet Pharmacodyn. 2003;30:239–56.PubMedCrossRefGoogle Scholar
  30. 30.
    Mollmann H, Wagner M, Krishnaswami S, Dimova H, Tang Y, Falcoz C, et al. Single-dose and steady-state pharmacokinetic and pharmacodynamic evaluation of therapeutically clinically equivalent doses of inhaled fluticasone propionate and budesonide, given as Diskus or Turbohaler dry-powder inhalers to healthy subjects. J Clin Pharmacol. 2001;41:1329–38.PubMedCrossRefGoogle Scholar
  31. 31.
    Thorsson L, Edsbacker S, Kallen A, Lofdahl CG. Pharmacokinetics and systemic activity of fluticasone via Diskus and pMDI, and of budesonide via Turbuhaler. Br J Clin Pharmacol. 2001;52:529–38.PubMedCrossRefGoogle Scholar
  32. 32.
    Mackie AE, Ventresca GP, Fuller RW, Bye A. Pharmacokinetics of intravenous fluticasone propionate in healthy subjects. Br J Clin Pharmacol. 1996;41:539–42.PubMedCrossRefGoogle Scholar
  33. 33.
    Krishnaswami S, Hochhaus G, Mollmann H, Barth J, Derendorf H. Interpretation of absorption rate data for inhaled fluticasone propionate obtained in compartmental pharmacokinetic modeling. Int J Clin Pharmacol Ther. 2005;43:117–22.PubMedGoogle Scholar
  34. 34.
    Berridge MS, Lee Z, Heald DL. Pulmonary distribution and kinetics of inhaled [11C]triamcinolone acetonide. J Nucl Med. 2000;41:1603–11.PubMedGoogle Scholar
  35. 35.
    Harrison TW, Tattersfield AE. Plasma concentrations of fluticasone propionate and budesonide following inhalation from dry powder inhalers by healthy and asthmatic subjects. Thorax. 2003;58:258–60.PubMedCrossRefGoogle Scholar
  36. 36.
    Mortimer KJ, Tattersfield AE, Tang Y, Wu K, Lewis S, Hochhaus G, et al. Plasma concentrations of fluticasone propionate and budesonide following inhalation: effect of induced bronchoconstriction. Br J Clin Pharmacol. 2007;64:439–44.PubMedCrossRefGoogle Scholar
  37. 37.
    Dalby C, Polanowski T, Larsson T, Borgstrom L, Edsbacker S, Harrison TW. The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. Respir Res. 2009;10:104.PubMedCrossRefGoogle Scholar
  38. 38.
    Argenti D, Shah B, Heald D. A study comparing the clinical pharmacokinetics, pharmacodynamics, and tolerability of triamcinolone acetonide HFA-134a metered-dose inhaler and budesonide dry-powder inhaler following inhalation administration. J Clin Pharmacol. 2000;40:516–26.PubMedCrossRefGoogle Scholar
  39. 39.
    Hirst PH, Pitcairn GR, Richards JC, Rohatagi S, Gillen MS, Newman SP. Deposition and pharmacokinetics of an HFA formulation of triamcinolone acetonide delivered by pressurized metered dose inhaler. J Aerosol Med. 2001;14:155–65.PubMedCrossRefGoogle Scholar
  40. 40.
    Mollmann H, Derendorf H, Barth J, Meibohm B, Wagner M, Krieg M, et al. Pharmacokinetic/pharmacodynamic evaluation of systemic effects of flunisolide after inhalation. J Clin Pharmacol. 1997;37:893–903.PubMedGoogle Scholar
  41. 41.
    Nolting A, Sista S, Abramowitz W. Flunisolide HFA vs flunisolide CFC: pharmacokinetic comparison in healthy volunteers. Biopharm Drug Dispos. 2001;22:373–82.PubMedCrossRefGoogle Scholar
  42. 42.
    Nolting A, Sista S, Abramowitz W. Single-dose study to compare the pharmacokinetics of HFA flunisolide and CFC flunisolide. J Pharm Sci. 2002;91:424–32.PubMedCrossRefGoogle Scholar
  43. 43.
    Richards J, Hirst P, Pitcairn G, Mahashabde S, Abramowitz W, Nolting A, et al. Deposition and pharmacokinetics of flunisolide delivered from pressurized inhalers containing non-CFC and CFC propellants. J Aerosol Med. 2001;14:197–208.PubMedCrossRefGoogle Scholar
  44. 44.
    Zaborny BA, Lukacsko P, Barinov-Colligon I, Ziemniak JA. Inhaled corticosteroids in asthma: a dose-proportionality study with triamcinolone acetonide aerosol. J Clin Pharmacol. 1992;32:463–9.PubMedGoogle Scholar
  45. 45.
    Gonda I. Drugs administered directly into the respiratory tract: modeling of the duration of effective drug levels. J Pharm Sci. 1988;77:340–6.PubMedCrossRefGoogle Scholar
  46. 46.
    Hofmann W. Modelling inhaled particle deposition in the human lung—a review. J Aerosol Sci. 2011;42:693–724.CrossRefGoogle Scholar
  47. 47.
    Mortimer KJ, Harrison TW, Tang Y, Wu K, Lewis S, Sahasranaman S, et al. Plasma concentrations of inhaled corticosteroids in relation to airflow obstruction in asthma. J Clin Pharmacol. 2006;62:412–9.Google Scholar
  48. 48.
    Byron PR, Hindle M, Lange CF, Longest PW, McRobbie D, Oldham MJ, et al. In vivoin vitro correlations: predicting pulmonary drug deposition from pharmaceutical aerosols. J Aerosol Med Pulm Drug Deliv. 2010;23 Suppl 2:S59–69.PubMedGoogle Scholar
  49. 49.
    Son Y-J, Horng M, Copley M, McConville JT. Optimization of an in vitro dissolution test method for inhalation formulations. Dissolution Technologies. 2010;1–8:6–13.Google Scholar
  50. 50.
    Rohatagi S, Bye A, Mackie AE, Derendorf H. Mathematical modeling of cortisol circadian rhythm and cortisol suppression. Eur J Pharm Sci. 1996;4:341–50.CrossRefGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2012

Authors and Affiliations

  1. 1.Department of Pharmaceutics, College of Pharmacy, Center of Pharmacometrics and Systems PharmacologyUniversity of FloridaGainesvilleUSA

Personalised recommendations